Biologics Commonly Used in Cutaneous Crohn Disease - Takeaways - MDSpire

Biologics Commonly Used in Cutaneous Crohn Disease

  • By

  • Andrea Surnit

  • May 27, 2026

Share

  • 1

    A retrospective study found that most patients with cutaneous Crohn disease improved after receiving biologic or small-molecule inhibitor therapy.

  • 2

    The study reviewed data from 57 patients, with 81% being female and a mean diagnosis age of 37 years.

  • 3

    Genital involvement was the most common cutaneous presentation, occurring in 44% of patients.

  • 4

    Tumor necrosis factor alpha inhibitors were the most frequently prescribed biologics, used in 85% of treated patients.

  • 5

    The study's limitations include its uncontrolled design and variability in treatment regimens across institutions.

Original Source(s)

Biologics Commonly Used in Cutaneous Crohn Disease

  • by Andrea Surnit

  • May 27, 2026

Related Content

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

Pediatric Dermatology Clinic now accepting referrals for complex cases

This program provides subspecialty expertise in the diagnosis and management of complex pediatric dermatologic diseases.

  • by

  • May 14, 2026

  • 1 min